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Chronic melatonin treatment rescues electrophysiological and
neuromorphological deficits in a mouse model of Down syndrome
Abstract: The Ts65Dn mouse (TS), the most commonly used model of Down
syndrome (DS), exhibits several key phenotypic characteristics of this
condition. In particular, these animals present hypocellularity in different areas
of their CNS due to impaired neurogenesis and have alterations in synaptic
plasticity that compromise their cognitive performance. In addition, increases
in oxidative stress during adulthood contribute to the age-related progression
of cognitive and neuronal deterioration. We have previously demonstrated
that chronic melatonin treatment improves learning and memory and reduces
cholinergic neurodegeneration in TS mice. However, the molecular and
physiological mechanisms that mediate these beneficial cognitive effects are not
yet fully understood. In this study, we analyzed the effects of chronic
melatonin treatment on different mechanisms that have been proposed to
underlie the cognitive impairments observed in TS mice: reduced neurogenesis,
altered synaptic plasticity, enhanced synaptic inhibition and oxidative damage.
Chronic melatonin treatment rescued both impaired adult neurogenesis and
the decreased density of hippocampal granule cells in trisomic mice. In
addition, melatonin administration reduced synaptic inhibition in TS mice by
increasing the density and/or activity of glutamatergic synapses in the
hippocampus. These effects were accompanied by a full recovery of
hippocampal LTP in trisomic animals. Finally, melatonin treatment decreased
the levels of lipid peroxidation in the hippocampus of TS mice. These results
indicate that the cognitive-enhancing effects of melatonin in adult TS mice
could be mediated by the normalization of their electrophysiological and
neuromorphological abnormalities and suggest that melatonin represents an
effective treatment in retarding the progression of DS neuropathology.
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Introduction
Ts65Dn mice (TS), the most commonly used model of
Down syndrome (DS), exhibit numerous phenotypic char-
acteristics of DS, including cognitive deficits due to
impairments in hippocampal morphology and function [1].
These cognitive impairments appear in early life stages [2,
3] and become more pronounced during adulthood [4, 5].
One of the neuromorphological substrates of the cogni-
tive deficits in TS mice and in DS individuals is the hypo-
cellularity found in different areas of the central nervous
system (CNS), including the hippocampus, presumably
due to reduced neurogenesis. Altered pre- and postnatal
neurogenesis has been demonstrated in individuals with
DS and in TS mice and has been implicated in the cogni-
tive deficits found in both conditions [1, 6]. Restoring
neurogenesis by administering fluoxetine, lithium or the
a5-selective negative allosteric modulator of the GABAA
receptor RO4938581 restores cognitive abilities in the TS
mouse model of DS [2, 7, 8]. Adult hippocampal neuro-
genesis has an important role in the establishment of
hippocampal long-term potentiation (LTP) [9, 10], which
is considered to be the electrophysiological substrate of
learning and memory [11]. TS mice show a marked reduc-
tion in LTP in the CA1 and DG areas that correlates with
their cognitive deficits [12–15].
One of the mechanisms proposed to underlie this
altered synaptic plasticity in TS animals is enhanced
inhibition due to an imbalance between excitatory and
inhibitory neurotransmission. TS mice have increased
GABA-mediated inhibition and a concomitant decrease
in glutamatergic transmission resulting in impaired hip-
pocampal LTP [12–16]. Different pharmacological manip-
ulations that restore or improve the balance between
excitatory and inhibitory transmission rescue neural plas-
ticity and cognitive abilities in the TS mouse model of
DS [7, 17–19].
Another mechanism that has been implicated in altering
cognitive and neuronal function in DS is increased oxida-
tive stress. In early life stages, DS individuals present
enhanced oxidative stress including elevated levels of lipid
peroxidation [20–24], which can modify processes such as
neurogenesis, differentiation, migration, net connection
and neuronal survival [23–25]. In later life stages, oxidative
stress can also contribute to the age-related progression of
cognitive and neuronal degeneration associated with DS
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[26–28]. Both DS individuals and TS mice overexpress
SOD1, the gene responsible for the formation of superox-
ide dismutase, an enzyme that modifies oxygen free radi-
cals into hydrogen peroxide, leading to the overproduction
of highly reactive oxygen free radicals. In addition, in DS,
the overexpression of the APP gene leads to the overpro-
duction of Ab peptides and plays a pivotal role in the reg-
ulation of oxidative stress [28].
Melatonin is an indoleamine that has been consistently
demonstrated to have neuroprotective effects [29–32].
Among the mechanisms underlying these effects are its free
radical–scavenging and antioxidant properties [33, 34], its
beneficial effect on neurogenesis [29, 30] and its ability to
promote structural and functional neuroplasticity [30, 35–
38]. Furthermore, it improves cognitive deficits in various
mouse models of different neuropathologies [30, 31, 39].
These studies suggest that melatonin could be a useful tool
to improve the functional and neuromorphological abnor-
malities of the DS brain.
In a previous study, we showed that chronic melatonin
treatment improves spatial learning and memory and
delays the degeneration of cholinergic neurons in adult TS
mice [40]. The aim of the present study was to evaluate the
mechanisms by which melatonin exerts its cognitive-
enhancing effects in TS mice. Therefore, we have studied
the effect of chronic treatment with this indoleamine on
adult hippocampal neurogenesis, on synaptic plasticity, on
excitatory/inhibitory balance and on brain lipid peroxida-
tion in middle-aged TS mice.
Material and methods
Animals and housing
This study was approved by the Cantabria University
Institutional Laboratory Animal Care and Use Committee
and was carried out in accordance with the Declaration of
Helsinki and the European Communities Council Direc-
tive (86/609/EEC). Mice were generated by repeated back-
crossing of B6EiC3Sn a/A-Ts(17<16>)65Dn (TS) females
with C57BL/6Ei x C3H/HeSNJ (B6EiCSn) F1 hybrid
males. The parental mouse generation was provided by the
Robertsonian Chromosome Resources (The Jackson Lab-
oratory, Bar Harbor, ME, USA), and mating was per-
formed in the University of Cantabria animal facilities. In
all experiments, TS mice were compared to euploid litter-
mates (CO). To determine the presence of the trisomy, ani-
mals were karyotyped using real-time quantitative PCR
(qPCR) as previously described [41]. Because C3H/HeSnJ
mice carry a recessive mutation that leads to retinal degen-
eration (RD), all animals were genotyped by standard
PCR to identify and exclude mice carrying this gene. Mice
were housed individually and maintained under a 12/12 hr
light/dark cycle. Mice were allowed free access to rodent
chow and water.
In this study, two cohorts of male mice were used. In
the first cohort, eight animals per group (CO-vehicle; CO-
Mel; TS-vehicle; TS-Mel) were used to perform the immu-
nohistochemical studies (neurogenesis and inhibitory and
excitatory synapse markers). The second cohort (CO-vehi-
cle = 11; CO-Mel = 9; TS-vehicle = 9; TS-Mel = 9) was
used to evaluate the effects of melatonin on LTP and brain
oxidative stress.
Melatonin treatment
TS and CO male mice were treated with either melatonin
(Mel) or its diluents (vehicle) and assigned to one of four
experimental groups: TS-Mel, CO-Mel, TS-vehicle, and
CO-vehicle. Melatonin (100 mg/L; Sigma-Aldrich,
Madrid, Spain) was dissolved in absolute ethanol and then
added to drinking water at a final ethanol concentration
of 0.06%. Fresh melatonin solution was prepared twice a
week in feeding bottles that were protected from light. The
estimated daily melatonin intake for each mouse was
0.5 mg, based on an average daily water consumption rate
of 5 mL/day. TS and CO mice in the vehicle groups
received tap water containing 0.06% ethanol. Daily water
consumption was similar for all experimental groups. All
mice were 6–6.5 months old at the beginning of the treat-
ment and between 11 and 11.5 months of age at the time
of histological procedures. Those animals used for elec-
trophysiology and the ELISA assay continued receiving
treatment with melatonin or vehicle until they were
12 months-old.
Hippocampal LTP recording
Mice were decapitated, and the brains were rapidly
removed. The hippocampi were dissected, and 400 lm
slices were cut using a tissue chopper. Slices were allowed
to recover for at least 1 hr in an interface chamber at
room temperature in artificial cerebral spinal fluid (ACSF)
containing (in mM) 120 NaCl, 3.5 KCl, 2.5 CaCl2, 1.3
MgSO4, 1.25 NaH2PO4, 26 NaHCO3 and 10 D-glucose
(saturated with 95% O2 and 5% CO2). Field excitatory
postsynaptic potentials (fEPSPs) were recorded from the
CA1 stratum radiatum with a glass micropipette
(1–4 MΩ) containing 2 M NaCl and evoked by stimulation
of the Schaffer collaterals using insulated bipolar plati-
num/iridium electrodes >500 lm away from the recording
electrode. The stimulus strength was adjusted to evoke
fEPSPs that were equal to 50% of the relative maximum
amplitude, not including any superimposed population
spike. After stable baseline recordings (100 ls pulse-dura-
tion, 0.033 Hz), LTP was induced by theta burst stimula-
tion (TBS; 10 trains of 5 pulses at 100 Hz and intervals of
200 ms). The duration of the stimulation pulses was
doubled during the tetanus. fEPSPs were amplified, band-
pass-filtered (1 Hz-1 kHz) and stored in a computer using
the Spike2 program (Spike2, Cambridge Electronic
Design, Cambridge, UK). For analysis, fEPSP slopes were
expressed as percentages of the baseline values recorded.
Results from several slices were expressed as
means  S.E.M.
Immunohistochemistry
The animals used for histology and cell counting were dee-
ply anesthetized with pentobarbital and transcardially per-
fused with saline followed by 4% paraformaldehyde. After
being removed and postfixed in 4% paraformaldehyde
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overnight at 4°C and transferred into 30% sucrose, the
brains were frozen in dry ice and sliced coronally in a
cryostat (50 lm thick sections). Series of brain slices were
randomly made up of one section out of every nine for the
immunohistochemistry protocol. A randomly chosen series
was used to perform Nissl staining to calculate the sub-
granular zone (SGZ) total area of each mouse. The total
SGZ extension was measured by the standard Cavalieri
method as described previously by Llorens-Martin et al.
[42]2 using a semiautomatic system (ImageJ v.1.33, NIH,
USA, http://rsb.info.nih.gov/ij/3 ).
Mature granule cell count
Mature granule cells in the hippocampal granule cell layer
(GCL) were counted in series of one-in-nine sections
stained with 4′6-diamidino-2-phenylindole (DAPI, Calbio-
chem, 1:1000) for 10 min in 0.1 M phosphate buffer (PB).
Cell counts were performed using a previously described
physical dissector system coupled with confocal micros-
copy [42]. Random numbers were generated to select the
points at which to locate the dissectors. Six dissectors in
each section were measured. At the selected points, the
confocal microscope (Leica SPE4 ) was directed toward a
position previously established randomly inside the GCL.
Next, at each point, a series of confocal images was seri-
ally recorded, keeping to the general rules of the physical
dissector and the unbiased stereology. The confocal
images were then analyzed on a computer with the aid of
the ImageJ software (ImageJ, v. 1.33, NIH, Bethesda,
MD, USA, http://rsb.info.nih.gov/ij). Every successive
pair of images was used, with one considered as the refer-
ence image and the other the sample image. Next, the sam-
ple image became the reference image for the next pair of
images, and so on. The cells were counted with the NIH
ImageJ Cell Counter, labeling each cell on the screen the
first time it appears in the series of confocal images. The
software generated the total number of cells when the dis-
sector brick was completed. For counting the mature gran-
ule neurons in the GCL, the dissector frame was a square
situated randomly inside the GCL. The number of cells
was then divided by the reference volume of the dissector
(this parameter is the volume of a cube formed by the area
of the frame multiplied by the height of the dissector) to
obtain the number of cells per volume unit (cell density).
Cell proliferation in the SGZ (Ki67 immunofluorescence)
Slices were initially pre-incubated in PB with Triton X-100
0.5% and bovine serum albumin (BSA) 0.1%, and then
immunohistochemistry was performed as described previ-
ously [7]. Briefly, free-floating slices were incubated with
primary antibodies (rabbit anti-Ki67, 1:750; Neo Markers,
UK5 ) diluted in PB with Triton X-100 0.5% and BSA
0.1% (PBTBSA) for 2 days at 4°C. Then, slices were incu-
bated overnight at 4°C with secondary antibody (donkey
anti-rabbit-Alexa Fluor 488, 1:1000, Molecular Probes,
Eugene, OR, USA). The sections were counterstained with
DAPI and mounted in gelatin-covered slides to be ana-
lyzed and photographed. The total number of Ki67-posi-
tive cells was counted in the selected sections with the help
of an optical fluorescence microscope (Zeiss Axioskop 2
plus, 409 objective 6) using the optical dissector method
previously described [43].
Neurodifferentiation (doublecortin/calretinin immunofluores-
cence)
One-in-nine series of 50 lm sections of mouse brains were
used for the determination of cells expressing immature
markers: doublecortin (DCX) and/or calretinin (CLR).
Slices were initially preincubated in PBTBSA, and then
dual immunohistochemistry was performed as described
previously [42]. The primary antibodies used were goat
anti-doublecortin (1:250; Santa Cruz, USA 7) and rabbit
anti-calretinin (1:3000; Swant, Switzerland 8). The primary
antibodies were recognized with an Alexa Fluor 594-con-
jugated donkey anti-goat and an Alexa Fluor 488-conju-
gated donkey anti-rabbit antibody (Alexa-conjugated
antibodies from Molecular Probes, 1:1000). The sections
were incubated with both primary antibodies at the same
time and then with both secondary antibodies at the same
time. The sections were then analyzed and photographed
under a confocal microscope (Leica SP5 9). Quantification
of DCX and CLR expression was performed according to
stereological procedures of physical dissector previously
described by Llorens-Martin et al. [42]. At each point of
the section to be registered, we counted all the immature
cells in the reference area using ImageJ. Next, the number
was divided by the reference area of the side of the prism
aligned with the SGZ to obtain the number of cells per
area unit (the reference area for the side of the prism is the
length of the side of the frame multiplied by the height of
the dissector). The cell density was then multiplied by the
SGZ area to obtain the total number of cells for each of
the different populations of immature neurons. The num-
ber of immature neurons is presented as either DCX+/
CLR or total CLR+ (i.e. DCX+/CLR+ plus DCX/
CLR+).
Density of glutamatergic and GABAergic synapse markers
(VGLUT1 and GAD65 immunofluorescence)
One-in-nine series of 50 lm sections of mouse brains were
used for the determination of GABAergic and glutamater-
gic synapses. Slices were initially preincubated in
PBTBSA, and then dual immunohistochemistry was per-
formed as described previously [44]. Glutamatergic and
GABAergic boutons in the molecular layer (ML) of the
hippocampus were identified with anti-vesicular glutamate
transporter 1 (VGLUT1, 1:2500; Chemicon, Temecula,
CA, USA), a glutamatergic synapse marker, followed by
Alexa Fluor 488-conjugated goat anti-guinea pig Ig
(1:1000; Invitrogen, Carlsbad, CA, USA) and with anti-
glutamic acid decarboxylase (GAD65, 1:250; Chemicon), a
GABAergic synapse marker, followed by Alexa Fluor 594-
conjugated donkey anti-mouse Ig (1:1000; Invitrogen).
Measurements were performed in images obtained with
a confocal microscope (Leica SP5), using a 639 1.4 NA
objective and a 99 zoom. For each marker, four sections
per animal were used comprising the entire hippocampus,
and one random area in the hippocampus per section was
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measured. Image analysis was performed with the aid of
the NIH ImageJ software. Briefly, boutons with positive
immunofluorescence (either VGLUT1 or GAD65 because
these markers never colocalize) were measured separately
applying the same threshold to all pictures. Images were
first converted to grey scale to improve the contrast
between signal and noise. Areas were measured inside a
reference circle with a standard size of 325 lm2. A refer-
ence space was located in the inner ML of the hippocam-
pal DG, lining the most external layer of granule neurons
in the GCL. The percentage of reference area occupied by
VGLUT1- and GAD65- positive boutons was calculated.
Quantitation of lipid peroxidation in brain tissue
To quantify lipid peroxidation levels, 4-hydroxynonenal
(HNE) Adduct ELISA Kit (OxiSelectTM HNE Adduct
ELISA Kit, STA-338; Cell Biolabs, San Diego, CA, USA)
was used to detect and measure hippocampal and cortex
levels of HNE protein adducts in seven animals of each
group. Briefly, tissue samples were homogenized in 1X
PBS containing proteinase inhibitors (1:100, Protease
Inhibitor Cocktail Set III, Merck, Darmstadt, Germany)
and centrifuged at 12,000 g for 10 min. The supernatant
fraction was collected and stored at 80°C. The protein
concentration was determined with a Lowry protein assay,
and samples were diluted to 10 lg/mL. To quantify HNE
levels, supernatant fractions were analyzed using an HNE
Adduct ELISA Kit following the manufacturer′s instruc-
tions. Analyses were always performed in duplicate. OD450
values were detected on a microplate reader (Multiskan
EX; Thermo Electron Corporation, Vantaa, Finland).
HNE levels were calculated according to the standard
curve.
Statistical analysis
LTP data were analyzed by repeated-measures (RM)-
ANOVAs (‘time’ 9 ‘treatment’ 9 ‘genotype’). The remain-
ing neuromorphological and ELISA data were analyzed
using two-way (‘genotype’ 9 ‘treatment’) ANOVAs. The
means of each experimental group were compared post-
hoc by Student’s t-test if two groups were compared or by
Bonferroni tests if more than two groups were compared.
All of the analyses were performed using SPSS (version
21.0) 10for Windows. The F values of RM-ANOVAs, two-
way ANOVAs, and post hoc analysis of each independent
neuromorphological and electrophysiological variable
tested are shown in Table 1.
Results
Figure 1(A) shows the immunocytochemical detection of
mature granule neurons (DAPI+ cells) in the GCL of the
DG of TS and CO mice treated with either melatonin or
vehicle. The quantitative analysis of this cell population
showed that vehicle-treated TS mice had a significantly
lower density of DAPI+ cells than CO animals (P = 0.03).
Melatonin increased the density of DAPI+ cells in both
genotypes (P = 0.003; Table 1). After chronic treatment
with melatonin, the density of granule neurons was signifi-
cantly increased in the GCL of TS mice to levels similar to
those observed in vehicle-treated CO mice (TS-melatonin
versus CO-vehicle: P = 0.25; Fig. 1B). In CO mice, mela-
tonin slightly increased the density of DAPI+ cells,
although this effect did not reach statistical significance
(CO-melatonin versus CO-vehicle: P = 0.07; Fig. 1B).
Cells undergoing different stages of adult hippocampal
neurogenesis were identified and quantified using specific
markers for proliferation and differentiation. To estimate
the density of the actively dividing cells, we used Ki67
immunohistochemistry (Fig. 2B, up and second row). The
density of Ki67+ cells in the SGZ was reduced in vehicle-
treated TS mice compared to the vehicle-treated CO group
(P < 0.001; Fig. 2C). Statistical analysis showed that mela-
tonin treatment significantly increased the density of
Ki67+ cells in TS mice compared to those of vehicle-trea-
ted TS mice (TS-vehicle versus TS-melatonin: P = 0.01;
Table 1; Fig. 2C). By contrast, melatonin treatment did
not modify the density of this cell population in CO mice.
Table 1. F values of RM-MANOVA, MANOVA (genotype x treatment) and post hoc analysis of each variable tested
Genotype Treatment Genotype 9 Treatment
Inmunohistochemistry
DAPI+ cells F1,29 = 4.99; P < 0.05 F1,29 = 11.00; P < 0.01 F1,29 = 0.05; P = 0.82
Ki67+ cells F1,29 = 27.73; P < 0.001 F1,29 = 1.52; P = 0.22 F1,29 = 1.16; P = 0.29
DCX+ cells F1,29 = 3.89; P = 0.059 F1,29 = 7.61; P < 0.01 F1,29 = 1.52; P = 0.22
CLR+ cells F1,29 = 6.30; P < 0.05 F1,29 = 1.51; P = 0.22 F1,29 = 5.29; P < 0.05
GABAergic boutons (GAD65) F1,29 = 137.95; P < 0.001 F1,29 = 0.04; P = 0.99 F1,29 = 1.02; P = 0.32
Glutamatergic boutons (VGLUT) F1,29 = 28.49; P < 0.001 F1,29 = 13.57; P < 0.001 F1,29 = 4.46; P < 0.05
Levels of HNE
Cortex F1,25 = 9.64; P < 0.01 F1,25 = 6.91; P < 0.05 F1,25 = 2.20; P = 0.15
Hippocampus F1,25 = 2.50; P = 0.12 F1,25 = 0.29; P = 0.59 F1,25 = 2.82; P = 0.10
LTP results
Basal F1,35 = 0.19; P = 0.65 F1,35 = 0.01; P = 0.91 F1,35 = 0.19; P = 0.65
After theta burst stimulation F1,35 = 7.85; P < 0.01 F1,35 = 4.86; P < 0.05 F1,35 = 1.80; P = 0.18
Post hoc comparisons between each pair of potentiation curves
CO-Veh versus TS-Veh F1,17 = 11.09; P < 0.01
TS-Veh versus TS-mel F1,15 = 15.10; P < 0.001
CO-Veh versus CO-mel F1,17 = 0.25; P = 0.62
CO-Veh versus TS-mel F1,17 = 0.19; P = 0.66
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We then performed dual immunohistochemistry using
specific markers for the determination of proteins
expressed by different subpopulations of hippocampal neu-
rons in consecutive developmental stages in TS and CO
mice treated with either melatonin or vehicle (Fig. 2A).
For the determination of immature neurons, we performed
immunohistochemistry for the early neuronal marker
DCX in the different groups of mice (Fig. 2B, third row).
Vehicle-treated TS animals showed a reduced density of
DCX+ cells compared to CO animals (P = 0.003), and
chronic melatonin treatment rescued this alteration in TS
mice (P = 0.01; Fig 2C). Indeed, after chronic melatonin
treatment, TS mice did not differ in the number of DCX+/
CLR cells from vehicle-treated CO mice (CO-vehicle
versus TS-Mel: P = 0.58; Table 1; Fig. 2C).
Cells undergoing later differentiation stages were evalu-
ated using the neuronal marker CLR (Fig. 2B, fourth
row). The density of CLR+ cells (Fig. 2C; including both
DCX+/CLR+ and DCX/CLR+ phenotypes) was reduced
in TS mice compared to vehicle-treated-CO mice
(P = 0.018; CO-vehicle versus TS-vehicle: P = 0.006).
However, the density of CLR+ cells was normalized after
chronic melatonin treatment in TS mice (CO-vehicle
versus TS-Mel: P = 0.48; Fig. 2C).
Figure 3 shows the levels of HNE in the cortices and
hippocampi of TS and CO mice. Vehicle-treated TS mice
had increased levels of lipid peroxidation in the cortex
(P = 0.005) and in the hippocampus (P = 0.015; Table 1).
Melatonin administration significantly reduced the levels
of HNE in the cortex (P = 0.015) but not in the hippo-
campus (P = 0.59) of TS or CO animals. However, post
hoc analysis revealed that the increase in HNE levels in
the hippocampus of TS-vehicle mice compared to CO-
vehicle mice was no longer significant after melatonin
treatment (P = 0.42; Fig. 3).
To assess the effect of chronic melatonin treatment on
hippocampal synaptic plasticity in TS and CO mice, we
used a theta burst stimulus (TBS) to induce LTP in the
Schaffer collaterals-CA1 region (SC-CA1) of the hippo-
campus. No significant differences were found in fEPSP
amplitudes in the baselines of the four groups of
mice (P = 0.93, Table 1; Fig. 4). Analysis of fEPSPs in
vehicle-treated TS mice revealed deficits in TBS-induced
LTP in CA1 with respect to vehicle-treated CO mice
(P = 0.004; Fig. 4). Melatonin produced an enhancement
of LTP in TS mice (P = 0.001). These findings indicate that
chronic melatonin treatment completely rescued LTP in TS
mice, as the mean fEPSP slopes did not differ between
melatonin-treated TS mice and vehicle-treated CO mice
(P = 0.66; Fig. 4). However, chronic melatonin adminis-
tration did not modify LTP in CO animals (P = 0.62).
The analysis of the number of GABAergic (GAD65+)
and glutamatergic (VGLUT1+) synaptic boutons in the
hippocampal ML revealed that vehicle-treated TS mice
showed reduced VGLUT1 immunoreactivity (Fig. 5A,
upper row) and an increased area occupied by GAD65+
boutons compared to vehicle-treated CO mice (Fig. 5A,
lower row; VGLUT1; P < 0.001; GAD65; P < 0.001).
Remarkably, melatonin treatment significantly increased
the percentage of the area occupied by VGLUT1 boutons
in TS mice, but no changes in the GABAergic synapse
marker GAD65 were observed in this group of animals
(VGLUT1: P = 0.001; GAD65: P = 0.99; Table 1). In CO
animals, melatonin treatment did not modify the percent-
age of the area occupied by GABAergic or glutamatergic
boutons (Fig. 5B).
Discussion
In this study, we investigated the putative mechanisms that
mediate the cognitive-enhancing effects of chronic melato-
nin treatment in adult TS mice. In particular, we studied
the effects of melatonin on the main electrophysiological
and neuromorphological alterations that have been pro-
posed to underlie learning and memory deficits in the TS
mouse model of DS, i.e. reduced hippocampal cellularity,
adult neurogenesis, altered synaptic plasticity due to
enhanced inhibition and increased oxidative stress [1, 28,
45].
Reductions in neuronal number in different areas of the
CNS appear to compromise cognitive function in DS and
in the TS mouse. This hypocellularity is particularly
important in the hippocampus due to its major impact on
spatial learning and memory. As previously shown by
(A)
(B)Fig. 1. 12(A) Representative images of
DAPI in the DG region of hippocampus
of vehicle- and melatonin-treated TS and
CO mice. (B) Means  S.E.M. of the
density of mature granule neurons in the
GCL of TS and of CO mice treated with
melatonin or vehicle. *P < 0.05 TS versus
CO; #P < 0.05 melatonin versus vehicle;
Bonferroni post-hoc tests after significant
MANOVAs.
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numerous studies [7, 43, 46], the density of mature granule
neurons is reduced in the GCL of TS mice. This reduction
may be due to increased cell death and/or to reduced
proliferation in the SGZ. Interestingly, we found that
melatonin treatment rescued the density of granule cells in
TS mice.
Reduced neurogenesis is likely to be one of the mecha-
nisms implicated in the impaired learning and memory
(A)
(B) (C)
Fig. 2. 13(A) Time courses for the expression of specific molecular markers during different stages of adult DG neurogenesis. Modified from
Contestabile et al. [8]. (B) Representative images of Ki67 (up row), coimmunostaining of Ki67 and DAPI (second row) and of immature
neurons expressing DCX (third row) and CLR (fourth row) in the DG of TS and CO mice treated with vehicle or melatonin. (C)
Means  S.E.M. of the density of Ki67+ cells and of immature neurons DCX+/CLR and CLR+ neurons in the SGZ of the hippocam-
pus of vehicle- or melatonin- treated TS and CO mice. **P < 0.01; ***P < 0.001 TS versus CO; #P < 0.05, ##P < 0.01 melatonin versus
vehicle; Bonferroni post-hoc tests after significant MANOVAs.
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found in TS mice. Numerous studies have demonstrated
that adult hippocampal neurogenesis is important for nor-
mal spatial learning and memory. When newborn cells are
removed genetically, animals display impaired capacity for
learning and memory [10, 47]. Similarly, most of the treat-
ments that impair adult hippocampal neurogenesis also
disrupt spatial cognition [47, 48]. Indeed, a significant neg-
ative correlation has been observed between performance
in the Morris water maze (MWM) and the number of
newly generated cells derived from adult neurogenesis in
the DG of TS mice and euploid littermates [1, 49].
To evaluate the effects of chronic melatonin treatment
on adult hippocampal neurogenesis in TS mice, we ana-
lyzed different subpopulations of newborn cells (Ki67-
positive cells) and of new neurons under different stages of
differentiation (identified by DCX- and CLR-labeling). In
accordance with the results of a number of studies [2, 43,
49–51], adult TS mice had a lower density of proliferating
cells and decreases in both populations of immature neu-
rons in the SGZ of the DG. This reduction in the density
of proliferating and differentiating cells is likely to be
responsible for the hypocellularity found in TS hippo-
campi.
Previous studies showed that exogenous melatonin
administration rescued or attenuated the reduction of
neurogenesis found during aging in normal mice [29, 37,
52] and in several models of different neuropathologies
[31, 53–55]. Similarly, our data demonstrate that in adult
TS mice, melatonin enhanced adult hippocampal neuro-
genesis by increasing the density of proliferating cells.
However, melatonin did not completely restore the den-
sity of progenitors under proliferation (Ki67+ cells) in TS
mice. In DS, AbPP contributes to impaired neurogenesis
by influencing neural precursor cell proliferation [56]. In
our previous work [40], melatonin did not reduce the
increased levels of AbPP expression in the hippocampus
of TS mice, which may contribute to the incomplete
recovery of cell proliferation in these animals. In addi-
tion, cell cycle disruptions and decreased cell proliferation
beginning at early developmental stages in the TS mouse
model of DS [2, 46, 57]. Thus, it is also possible that
because the melatonin treatment regimen in the present
study started at 6 months of age, the hypocellularity
established in early developmental stages was not affected
by this indoleamine treatment. Further studies will be
necessary to clarify whether early melatonin administra-
tion may exert larger beneficial effects on cell prolifera-
tion in TS mice.
Melatonin completely rescued the density of immature
neurons undergoing different stages of differentiation by
normalizing the density of cells in intermediate DCX- and
CLR-expressing stages. In agreement with this result, in
vitro and in vivo studies have demonstrated that melato-
nin predominantly facilitates the transformation of precur-
sor cells into mature neurons in the SVZ and SGZ of the
adult mice [29, 58].
Fig. 3. 14Means  S.E.M. of the HNE levels in the cortex and hip-
pocampus of vehicle-or melatonin-treated TS and CO mice (n = 7
animals of each group). *P < 0.05; **P < 0.01 TS versus CO;
#P < 0.05 vehicle-treated versus melatonin-treated mice. Bonfer-
roni post-hoc tests after significant MANOVAs.
(A)
(B)
Fig. 4. 15(A) Representative fEPSPs traces
recorded before issuing the stimulus
(black) and at 60 min after stimulation
(red) for each experimental group. Scale
bars are 1 mV and 10 ms. (B)
Means  S.E.M. of fEPSPs (expressed as
% versus basal) values from vehicle-
treated CO (n = 11 slices from 11
different mice), vehicle-treated TS (n = 9
slices from 9 different mice), melatonin-
treated CO (n = 9 slices from 9 different
mice) and melatonin-treated TS (n = 9
slices from 9 different mice), respectively.
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Increase cell death is another putative mechanism impli-
cated in the hippocampus hypocellularity and the altered
cognitive abilities found in TS mice. Indeed, melatonin has
been shown to induce neuroprotection due to its anti-
apoptotic action through the prevention of the activation
of the mitochondrial pathway [59].However, previous
studies showed that apoptotic cell death during develop-
ment or in adulthood is not involved in the reduced num-
ber of neurons found in the TS brain [60, 61]. Therefore, it
is more likely that melatonin rescues the density of mature
granule neurons in the hippocampus by increasing adult
neurogenesis and survival.
Both DS individuals and TS mice present enhanced oxi-
dative stress leading to premature neuronal death and cog-
nitive dysfunction [22, 23, 62]. Consistent with previous
results [22, 62], the levels of HNE, a specific marker of
lipid peroxidation, were significantly increased in the hip-
pocampus of vehicle-treated TS mice compared to CO
mice. By contrast, TS mice did not show higher levels of
HNE in cortex, suggesting that this region may exhibit
more tolerance against oxidative stress than the hippo-
campus.
Melatonin rescued the levels of HNE in the hippocam-
pus of TS mice; thus, its cognitive-enhancing effects in
trisomic animals could also be partially due to its well-
known antioxidant properties [33, 39, 63]. Although the
antioxidant SGS-111, an analogue of the nootropic pirace-
tam, administered from conception failed to improve
learning and memory in the TS mouse model of DS [64],
other antioxidants, such as vitamin E, delay impairment in
cognitive performance, preserve markers of cholinergic cell
survival, sustain hippocampal morphology and normalize
oxidative stress in adult TS mice [62]. The free radical
scavenging ability of melatonin is twice that of vitamin E
[65], and melatonin is particularly effective in crossing the
blood-barrier [66]. Thus, the reduction in lipid peroxi-
dation in the hippocampus of TS mice after melatonin
treatment might be implicated in the increase in granule
cell density and the decrease in age-associated cognitive
decline observed in these animals.
Numerous studies have demonstrated that TS mice pres-
ent altered hippocampal synaptic plasticity that correlates
with their cognitive alterations. In agreement with previ-
ous evidence [13–15], the present study showed that LTP
was reduced in TS mice, and melatonin treatment for
5–6 months completely rescued LTP in the CA1 area in
trisomic animals. Consistent with these findings, chronic
melatonin treatment has been shown to rescue deficits in
hippocampal LTP and spatial memory after intra-hippo-
campal injection of Ab [30], although the acute application
of melatonin directly to mouse and rat hippocampal slices
inhibits LTP in the CA1 region [67–69].
Increasing evidence indicates that impaired LTP and the
associated cognitive dysfunction in TS animals are medi-
ated by a dysregulation between excitatory and inhibitory
neurotransmission [15, 16, 19]. Consistent with previous
results [7, 51], TS mice presented a reduced density of
glutamatergic (VGLUT1-positive boutons) and an
increased density of GABAergic (GAD65-positive bou-
tons) synapse markers in the hippocampal ML indicating
enhanced inhibition. Chronic melatonin administration to
adult TS mice increased the density of glutamatergic syn-
apse markers, thereby reducing inhibition. By contrast,
this treatment did not have any effect on the area occupied
by GAD65-positive boutons. Reducing synaptic inhibition
by administering different antagonists and negative alloste-
ric modulators of the GABAA receptor has been proven to
rescue synaptic plasticity, neuromorphological and cogni-
tive alterations in the TS mouse model of DS [7, 17, 18].
In addition, LTP in the SC-CA1 pathway is known to be
dependent upon the activation of NMDA receptors.
Recently, a high-affinity selective GABAB antagonist
improved LTP in TS mice by increasing the NMDA recep-
tor-mediated component [19]. Melatonin also protects and
(B)
(A)
(C)
Fig. 5.16 (A) Representative confocal
microscope images of boutons
immunopositive for VGlut1 (green,
glutamate synapses; up row) and GAD65
(red, GABAergic synapses; down row) in
the inner ML of the hippocampal DG,
lining the most external layer of granule
neuron in the GCL of the four groups of
animals. Means  S.E.M. of the
percentage of total immunopositive
surface occupied by VGlut1 (B) and
GAD65 (C) boutons of vehicle- and
melatonin-treated TS and CO mice.
**P < 0.01; ***P < 0.001 TS versus CO;
###P < 0.001 melatonin vs. vehicle;
Bonferroni post-hoc tests after significant
MANOVAs.
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increases NMDA receptor subunits 2A and 2B concentra-
tions in rat hippocampus [70, 71]. Thus, at the postsynap-
tic level, the enhanced activation of NMDA receptors
represents a possible mechanism by which melatonin could
increase LTP in TS mice. Melatonin administration to TS
mice might also restore LTP by increasing the density
and/or activity of glutamatergic synapses. In addition, the
restoration of the density of granule cells could improve
afferent synaptic input from the DG and enhance the
efficiency of excitatory signaling through the trisynaptic
circuit, thereby enhancing LTP.
In young TS mice, several pharmacotherapies, includ-
ing several selective GABAB receptor antagonists, the
selective GABAA a5 negative allosteric modulator
RO4938581, lithium, fluoxetine and the long-acting b2
adrenergic agonist formoterol, have been shown to
improve or normalize their cognitive performance, con-
comitantly to their neuromorphological and electrophysi-
ological deficits [7, 8, 19, 72, 73]. In aged TS animals,
like the ones used in this study, several drugs including
the uncompetitive NMDA receptor antagonist meman-
tine, the antioxidant vitamin E and the anti-inflammatory
drug minocycline have also been reported to reduce the
cognitive deterioration of these mice, and some age-
related neuropathological hallmarks of DS [51, 62, 74].
However, none of these treatments have been proven to
completely rescue the neuromorphorphological and elec-
trophysiological deficits proposed to underlie DS-cogni-
tive alterations as demonstrated in this work after
chronic melatonin treatment. In addition, melatonin is
normally well tolerated in adults, does not induce impor-
tant side-effects and has been approved for human use;
therefore, this indoleamine is a promising preventive
therapy to slow the age-related progression of DS cogni-
tive alterations.
In summary, melatonin administration to adult TS mice
significantly increased the density of proliferating cells, the
density of differentiating neuroblasts, and the density of
mature granule cells while reducing the levels of lipid per-
oxidation. Furthermore, it reduced synaptic inhibition in
the hippocampus of TS animals, leading to a complete
recovery of LTP. Therefore, the normalization of the func-
tion and/or morphology of the hippocampus is likely to
account for the cognitive-enhancing effects of chronic mel-
atonin treatment previously demonstrated in TS mice. Our
results provide evidence supporting the use of melatonin
in clinical trials to alleviate cognitive deficits in the DS
population prior to advanced memory decline. Regarding
its efficacy as a preventive therapy in adults with DS, the
initial dose, derived from this study to be administered to
humans could be calculated according to the body surface
area (BSA) normalization method previously described by
Reagan-Shaw et al. [75].
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